Article
Enasidenib causes clinically relevant rosuvastatin accumulation leading to toxic myopathy
2024-02-20
Abstract excerpt
A woman in her 80s developed AML while on rosuvastatin secondary prevention. IDH2 mutation was identified and Enasidenib was commenced as second line therapy and later presented with clinical, biochemical and radiographic evidence of myositis, without an alternative cause. We report the first case of enasidenib induced statin toxic myopathy, and discuss implications for AML patients most likely to receive this the...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bf10de83-c4b0-5f80-8d1f-68aeade0b02b
- DOI
- 10.21203/rs.3.rs-3949825/v1